A comprehensive view of Injectables / Infusions / IV Drips. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.
Pfizer gains FDA approval for BEQVEZ, a one-time dose treatment for adults with moderate to severe hemophilia B; the treatment is currently under review in Europe and was recently approved in Canada
Published:
April 26, 2024
by Pfizer Inc.
|
Par Pharmaceutical expands recall to include seven lots of Treprostinil Injection 20mg/20mL due to the possibility of silicone particulates in the product; affected product is distributed in 20mL multidose vials as sterile solutions in water for injection
Published:
April 23, 2024
by PR Newswire
|
Eli Lilly to acquire FDA-approved manufacturing facility from Nexus Pharmaceuticals to expand its injectable product manufacturing and meet increased demands; production at the Pleasant Prairie, Wisconsin, facility projected to start by end of 2025
Published:
April 22, 2024
by Eli Lilly & Co.
|
FDA approves subcutaneous administration of Takeda’s ENTYVIO (vedolizumab) for maintenance therapy in moderately to severely active Crohn’s Disease
Published:
April 19, 2024
by Business Wire
|
Health Canada approves Merck & Co's KEYTRUDA in combination with chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma treatment following successful Phase 3 trial
Published:
April 19, 2024
by EquityBites
|
Ask us about our R&D/Patents market view